Long-term anticoagulation in patients with coronary disease, and future developments

Current Opinion in Cardiology

Volumn 23, Issue 4, 2008, Pages 315-319

  Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aspirin; Factor Xa blockers; Myocardial infarction; Prognosis; Thrombin blockers; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DABIGATRAN; ENOXAPARIN; HEPARIN; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; FIBRINOLYSIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ST SEGMENT ELEVATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; HUMANS; MYOCARDIAL INFARCTION; RECURRENCE;

EID: 44649181592     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283021aef     Document Type: Review

References (28)

1. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303:897-902.
2. Rentrop KP, Blanke H, Karsch KR, et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979; 2: 354-363.
3. Serruys PW, Arnold AE, Brower RW, et al. Effect of continued rt-PA admission on the residual stenosis after initially successful recanalization in acute myocardial infarction. A quantitative coronary angiography study of a randomized trial. Eur Heart J 1987; 8:1172-1181.
4. Davies MJ, Thomas AC. Thrombosis and acute coronary artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310:1137-1140.
5. Willich SN, Linderer T, Wegschneider K, et al. Increased morning incidence of myocardial infarction in the ISAM study: absence with prior β-adrenergic blockade. Circulation 1989; 80:853-858.
6. Andreotti F, Kluft C, Davies GJ, et al. Effect of propranolol (long-acting) on the circadian fluctuation of tissue-plasminogen activator and plasminogen activator inhibitor-1. Am J Cardiol 1991; 68:1295-1299.
7. Keeley EC, Boura JA, Grines CL. Primary coronary angioplasty versus intravenous fibrinolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361:13-20.
8. Bahit MC, Topol EJ, Califf RM, et al. Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. J Am Coll Card 2001; 37: 1001-1007.
9. Brouwer MA, Verheugt FWA. Oral anticoagulants in acute coronary syndromes. Circulation 2002; 105:1270-1274.
10. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Card 2003; 41 (Suppl S):62S-69S.
11. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end-points analysis from the ATACS trial. Circulation 1994; 89:81-88.
12. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350:389-396.
13. The Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol 2001; 37:475-484.
14. Fiore LD, Ezekowitz MD, Brophy MT, et al., for the Combination Hemotherapy and Mortality Prevention (CHAMP) Study Group. Department of veteran affairs cooperative studies program clinical trial comparing combined warfarin and asprin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study. Circulation 2002; 105:557-563.
15. Brouwer MA, Van den Bergh PJPC, Vromans RPJW, et al. Aspirin plus medium intensity coumadin versus aspirin alone in the prevention of reocclusion after successful thrombolysis for suspected acute myocardial infarction: results of the APRICOT-2 study. Circulation 2002; 106:659-665.
16. Van Es RF, Jonker JJC, Verheugt FWA, et al. Aspirin, coumadin or both after acute coronary syndromes: results of the ASPECT-2 trial. Lancet 2002; 360:109-113.
17. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347:969-974.
18. Williams MJA, Morison IM, Parker JH, Stewart RH. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. J Am Coll Cardiol 1997; 30:364-369.
19. Wallentin L, Dellborg DM, Lindahl B, et al. The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study. Clin Cardiol 2001; 24 (Suppl I):12-14.
20. Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low molecular weight heparin, with unfractionated heparin adjunctive to tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104:648-652.
21. Simoons ML, Alonso A, Krzeminska-Pakula M, et al. Early ST segment elevation resolution: predictor of outcome and angiographic patency in patients with acute myocardial infarction. Results of the AMI-SK study. Eur Heart J 2002; 23:1282-1290.
22. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354:1477-1488.
23. Herlitz J, Holm J, Peterson M, et al. Effect of low dose warfarin added to aspirin long term after acute myocardial infarction on cardiovascular death, reinfarction and stroke. Eur Heart J 2004; 25:232-239.
24. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362:789-797.
25. Verheugt FWA. Can we pull the plug for warfarin in atrial fibrillation? Lancet 2003; 362:1686-1687.
26. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 2007; 100:1419-1426.
27. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic Deep-Vein Thrombosis) study. Circulation 2007; 116:180-187.
28. Turpie AGG. New anticoagulants in atrial fibrillation. Eur Heart J 2008; 29:155-165. Comprehensive update on novel oral anticoagulants (thrombin blockers and Xa antagonists) in general and in atrial fibrillation in particular.